Amnioreduction in Polyhydramnios

The aim of this work is to review the indications, procedural complications and outcomes of amnioreduction in pregnancies complicated by polyhydramnios.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Polyhydramnios Female Urogenital Diseases and Pregnancy Complications Pregnancy Complications Urogenital Diseases

Sex eligibility

Female

Study type

Observational

Primary location

Women's Health Hospital

Asyut, Egypt

Location contact

Mohamed Fekry

CONTACT

[email protected]

0882312388

Mohamed Fekry, PhD

PRINCIPAL_INVESTIGATOR

About this study

Polyhydramnios is the presence of excessive amniotic fluid in the amniotic sac and it's prevalence reaches 2% of all pregnancies . Polyhydramnios is diagnosed based on ultrasound criteria, as an amniotic fluid index (AFI) >25 cm or maximal vertical pocket > 8 cm . There is a recognized association of polyhydramnios and adverse pregnancy outcomes, including perinatal death, fetal abnormality and preterm birth . Management of the pregnancy can be problematic, particularly in severe cases, due to issues surrounding maternal discomfort and the risk of preterm birth. Amnioreduction, widely used in the management of polyhydramnios, is an option available to palliate maternal symptomatology and potentially prolong the pregnancy . Previous publications have shown a reduction in the risk for premature rupture of membranes and preterm labor decrease, placental perfusion improvement, and relief of maternal discomfort following amnioreduction

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pregnant women 20- 38 weeks
Patients with polyhydramnios

Exclusion criteria

Lethal fetal anomalies
Pre labor rupture of membranes
Placental separation
Chorioamnionitis

Treatment and study plan

Primary outcomes

Gestational age at delivery

Time frame: 4 months

Determine Gestational age at delivery in polyhydramnios patients . Increased age is good.
Rate of PROM

Time frame: 4 months

Number of cases developed PROM

Study contacts

Contact information is provided by the study sponsor or research team.

Mohamed Fekry, PhD

CONTACT

[email protected]

0882312388

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Benefits and Risks of Amnioreduction for Management of Pregnant Women With Polyhydramnios

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jul 16, 2025
Registry last updated: Jul 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed